

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

214919Orig1s000

Trade Name: GLYCOPYRROLATE INJECTION

Generic or Proper Name: GLYCOPYRROLATE INJECTION

Sponsor: Fresenius Kabi USA, LLC

Approval Date: April 21, 2022

Indication: Glycopyrrolate injection is used in anesthesia (adult and pediatric patients)

- for reduction of airway or gastric secretions, and volume and acidity of gastric secretions, and blockade of cardiac inhibitory reflexes during induction of anesthesia and intubation.
- intraoperatively to counteract surgically or drug-induced or vagal reflex associated arrhythmias.
- for protection against peripheral muscarinic effects of cholinergic agents.

Glycopyrrolate injection is used in peptic ulcer (adults)

- as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or oral medication is not tolerated.

CENTER FOR DRUG EVALUATION AND RESEARCH

214919Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Officer/Employee List	X
Multidiscipline Review(s) • Summary Review • Office Director • Cross Discipline Team Leader • Clinical • Non-Clinical • Statistical • Clinical Pharmacology	X
Product Quality Review(s)	X
Clinical Microbiology / Virology Review(s)	
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

214919Orig1s000

APPROVAL LETTER



NDA 214919

NDA APPROVAL

Fresenius Kabi USA, LLC
Three Corporate Drive
Lake Zurich, IL 60047

Attention: Marcela Ruvalcaba
Associate Specialist, Regulatory Affairs

Dear Ms. Ruvalcaba:

Please refer to your new drug application (NDA) dated June 18 2021, and received June 21, 2021, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA), for glycopyrrolate injection.

This NDA provides for the use of glycopyrrolate injection

in anesthesia (adult and pediatric patients)

- for reduction of airway or gastric secretions, and volume and acidity of gastric secretions, and blockade of cardiac inhibitory reflexes during induction of anesthesia and intubation,
- intraoperatively to counteract surgically or drug-induced or vagal reflex associated arrhythmias, and
- for protection against peripheral muscarinic effects of cholinergic agents.

in peptic ulcer (adults)

- as adjunctive therapy for the treatment of peptic ulcer when rapid
- anticholinergic effect is desired or oral medication is not tolerated..

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, except with the minor revisions listed above [e.g., changes consistent with annual reportable changes under 314.70(d)], as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 214919.**” Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for glycopyrrolate injection shall be 24 months from the date of manufacture when stored at 20° to 25°C (68° to 77° F).

PROPRIETARY NAME

If you intend to have a proprietary name for this product, the name and its use in the labeling must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit a request for a proposed proprietary name review. (See the guidance for industry *Contents of a Complete Submission for the Evaluation of Proprietary Names*, and *PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2018 through 2022*.)

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

**POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS
UNDER SECTION 506B**

We remind you of your postmarketing commitments:

- 4242-1 Perform an extractables study on the container closure using an AET of (b) (4) ppm.

The timetable you submitted on March 28, 2022, states that you will conduct this study according to the following schedule:

Study Completion:	03/2023
Interim Report:	03/2023
Final Report Submission:	03/2023

- 4242-2: Perform a leachables stability study with testing at timepoints consistent with the approved drug product stability protocol and recommendations in ICH Q1A (R2) Stability Testing of New Drug Substances and Products.

The timetable you submitted on March 28, 2022, states that you will conduct this study according to the following schedule:

Study Completion:	03/2025
Interim Report #1 (Leachables data up to 12 months):	12/2025
Interim Report #2 (Leachables data up to 24 months):	12/2026
Interim Report #3 (Leachables data up to 36 months):	12/2027
Final Report Submission:	12/2027

Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients/subjects entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “**Postmarketing Commitment Protocol**,” “**Postmarketing Commitment Final Report**,” or “**Postmarketing Commitment Correspondence**.”

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.⁶

If you have any questions, call Allison Meyer, Senior Regulatory Health Project Manager at (301)796-1258.

Sincerely,

{See appended electronic signature page}

Rigoberto Roca, MD
Director
Division of Anesthesiology, Addiction Medicine,
and Pain Medicine
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
- Carton and Container Labeling

³ For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

⁶ <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

RIGOBERTO A ROCA
04/21/2022 10:07:16 AM